UK markets closed

Cosmo Pharmaceuticals N.V. (0RGI.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
69.44+0.08 (+0.11%)
At close: 06:06PM BST

Cosmo Pharmaceuticals N.V.

Riverside II
Sir John Rogerson’s Quay
Dublin 2
353 1 817 0370

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Mauro Severino AjaniFounder & Executive Chairman390.42kN/A1955
Mr. Alessandro E. Della Cha LL.MCEO & Executive Director1.03MN/A1963
Mr. Ngo Dinh NhanPresident of Cosmo Intelligent Medical DevicesN/AN/A1979
Mr. Giulio EvangelistiSVP of Manufacturing, Service and Security (IMD)N/AN/A1970
Mr. Niall DonnellyChief Financial OfficerN/AN/A1972
Mr. Marco LecchiChief Operating OfficerN/AN/A1964
Mr. Davide MalavasiQualified Person & Technical DirectorN/AN/A1973
Mr. Luigi LongoChief Scientific OfficerN/AN/A1979
Ms. Hazel WinchesterHead of Investor RelationsN/AN/A1971
Mr. Biagio ViganoChief People OfficerN/AN/A1974
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CHF.


Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers' diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy. It is also in the development of Breezula (clascoterone), a novel androgen receptor inhibitor that targets androgen receptors in the scalp, currently expecting phase III trials; Rifamycin SV MMX – IBS-D, a formulation to treat colonic infections and irritable bowel syndrome with diarrhoea, currently completed phase II proof of concept clinical trials; CB-03-10 (cortexolone 17 -valerate-21-propionate), an oral androgen receptor antagonist for treatment solid tumors, currently under phase I studies; and CB-01-33 (colesevelam) for the treatment of bile acid diarrhea, currently under preclinical studies. The company has development, distribution, and licensing agreements with Bausch Health, Ferring, China Medical System Holdings Limited, Medtronic, Parmascience Inc., RedHill Biopharma Ltd., Dr. Falk Pharma, Sun Pharmaceutical Industries Ltd., 3SBio, InfectoPharm, and Hyphens Pharma International Limited. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

Corporate governance

Cosmo Pharmaceuticals N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.